---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-138915"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:49:34.814034+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA accepts IND for first neoantigen-directed T-cell therapy from Adaptive-Genentech collaboration

## Summary
- FDA accepted IND for TCR-based T-cell therapy candidate; first from collaboration to enter clinical development.
- Therapy targets neoantigens identified via Adaptive's TCR discovery platform.
- Genentech responsible for clinical, regulatory, and commercialization efforts.
- Adaptive reaffirms FY2023 revenue guidance of $205-215 million.

## SEC filing metadata
- accession: 0001193125-23-138915
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312523138915/0001193125-23-138915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312523138915/d420874d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-138915
- JSON: https://secwatch.observer/filing/0001193125-23-138915.json
- Plain text: https://secwatch.observer/filing/0001193125-23-138915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.